Navigation Links
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
Date:5/6/2010

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, "We are very pleased with AEZS-108 gaining orphan-drug designation for ovarian cancer from the FDA as it would provide it with extra market exclusivity protection. We look forward to reporting the final results from our ongoing European Phase 2 study in ovarian and endometrial cancer, later this year."

About Orphan-Drug Designation

Orphan-drug designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication or if it demonstrates superior safety, efficacy, or a major contribution to patient care versus another drug of its type previously granted the designation for the same indication. It also provides tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

About Ovarian Cancer

Ovaria
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MINNEAPOLIS, MN , May 1, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has priced ... common stock at a price of $9.00 per share, ... option to purchase up to an additional 585,000 shares ... Company will be $35.1 million.  The offering is expected to ...
(Date:5/1/2015)... May 1, 2015 A new ... antithrombotic drugs will reach $22.4bn in 2019. That revenue ... Industry and Market Prospects 2015-2025 ,  published ... investigation is to provide forecasts and qualitative analyses of ... publisher and consultancy in London, UK ...
(Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... Highlights Include Clinical Trial Updates, BETHESDA, Md., ... NWBT; OTC Bulletin Board: NWBO), (the,"Company or NWBT"), ... and Chief Executive Officer, will deliver a presentation ... vaccines for the,treatment of cancer, at the "Next ...
... (July 17, 2008) Researchers at the U.S. Department of ... have won two R&D 100 Awards for innovative fluid ... been awarded 101 R&D 100 Awards since the awards ... R&D 100 Award -- dubbed the "Oscars of innovation" ...
... Opens at The O2 This Autumn, - With ... exhibition to premiere at The O2, Body,Worlds & The ... von Hagens, go on sale today., (Photo: ... In partnership with the producers of the sensation ...
Cached Biology Technology:Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 2Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 3
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... exists that people who lived or worked at Camp ... and 1985 were exposed to the industrial solvents tricholorethylene ... strong scientific evidence is not available to determine whether ... contaminants, says a new report from the National Research ...
... researchers have accelerated research into Multiple Sclerosis by discovering ... unravel the causes of MS and other autoimmune disease. ... in the prestigious journal Nature Genetics . ... mystery. This discovery reveals important new insights into the ...
... protein known to be overly active in breast cancer ... the structural composition of mammary tissue, potentially making it ... Lombardi Comprehensive Cancer Center at Georgetown University Medical Center ... in Washington, DC, the scientists report that the protein, ...
Cached Biology News:Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 2Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 3Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study 4Aussie and Kiwi researchers make double MS genetic discovery 2Protein linked to change in tissue that surround and support breast tumors 2
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
... • Heat activated ,• Eliminates ... temperature ,• Excellent specificity allows extension ... secondary structures ,• Leaves an 'A' ... modified form of GeneChoice DNA Polymerase ...
... Form: buffered aqueous solution. ... from complex carbohydrates and glycoproteins. It is ... conditions where the pH must be neutral ... Unit Definition: One ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: